Fulcrum under pressure on underwhelming losmapimod data in type of muscular dystrophy

Thinly traded micro cap Fulcrum Therapeutics (NASDAQ:FULC) is down 7% premarket on light volume in reaction to preliminary results from a Phase 2 clinical trial, ReDUX4, evaluating losmapimod in patients with facioscapulohumeral muscular dystrophy (FSHD), a rare muscle-wasting disorder primarily affecting those of the face, around the shoulder blades and upper arms.